Company intelligence / Profile preview

Igneous

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Igneous is a biotechnology company launched by Flagship Pioneering in May 2024 to develop a new class of programmable medicines for chronic diseases. The company's platform is designed to program the body's own cells to produce therapeutic proteins in a controlled and durable manner, aiming to provide long-term solutions for conditions that currently require frequent dosing. By leveraging advances in genetic programming and delivery, Igneous seeks to create redosable treatments that can be tailored to specific patient needs. The company is currently in the pre-clinical stage, focusing on building a robust pipeline of candidates for various high-burden chronic indications.

Therapeutic areas: Other
Modalities: Programmable medicinesmRNA-based drugsGenetic medicines
Industry: Biotech

Beyond the preview

Go deeper on Igneous.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Igneous.

Explore the full profile